Calidi Biotherapeutics, Inc. Selling, General and Administrative Expense
Calidi Biotherapeutics, Inc. (CLDI) reported Selling, General and Administrative Expense of $1.59 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-13
- Calidi Biotherapeutics, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $1.59M, a 48.16% decline year-over-year.
- Calidi Biotherapeutics, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $1.60M, a 39.32% decline year-over-year.
- Calidi Biotherapeutics, Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $2.11M, a 4.66% decline year-over-year.
- Calidi Biotherapeutics, Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $2.69M, a 12.56% decline year-over-year.
- Calidi Biotherapeutics, Inc. selling, general and administrative expense for fiscal 2025 was $10.50M, a 18.57% decline from fiscal 2024.
- Calidi Biotherapeutics, Inc. selling, general and administrative expense for fiscal 2024 was $12.90M, a 19.31% decline from fiscal 2023.
- Calidi Biotherapeutics, Inc. selling, general and administrative expense for fiscal 2023 was $15.98M, a 0.52% increase from fiscal 2022.
- Calidi Biotherapeutics, Inc. selling, general and administrative expense for fiscal 2022 was $15.90M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.59M 10-Q · filed 2026-08-13 | $3.19M 10-Q · filed 2026-08-13 | $5.30M derived: sum of 3 quarters · filed 2026-08-13 | $7.99M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.60M 10-Q · filed 2026-05-14 | $3.71M derived: sum of 2 quarters · filed 2026-05-14 | $6.39M derived: sum of 3 quarters · filed 2026-05-14 | $9.47M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $2.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $4.79M derived: sum of 2 quarters · filed 2026-03-27 | $7.87M derived: sum of 3 quarters · filed 2026-08-13 | $10.50M 10-K · filed 2026-03-27 |
| 2025-09-30 | $2.69M 10-Q · filed 2025-11-13 | $5.76M derived: sum of 2 quarters · filed 2026-08-13 | $8.39M 10-Q · filed 2025-11-13 | $10.61M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $3.07M 10-Q · filed 2026-08-13 | $5.71M 10-Q · filed 2026-08-13 | $7.92M derived: sum of 3 quarters · filed 2026-08-13 | $10.99M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $2.64M 10-Q · filed 2026-05-14 | $4.85M derived: sum of 2 quarters · filed 2026-05-14 | $7.92M derived: sum of 3 quarters · filed 2026-05-14 | $11.53M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $5.28M derived: sum of 2 quarters · filed 2026-03-27 | $8.89M derived: sum of 3 quarters · filed 2026-03-27 | $12.90M 10-K · filed 2026-03-27 |
| 2024-09-30 | $3.07M 10-Q · filed 2025-11-13 | $6.68M derived: sum of 2 quarters · filed 2025-11-13 | $10.69M 10-Q · filed 2025-11-13 | $16.55M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $3.60M 10-Q · filed 2025-08-08 | $7.61M 10-Q · filed 2025-08-08 | $13.48M derived: sum of 3 quarters · filed 2025-08-08 | $17.45M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $4.01M 10-Q · filed 2025-05-14 | $9.87M derived: sum of 2 quarters · filed 2025-05-14 | $13.84M derived: sum of 3 quarters · filed 2025-05-14 | $17.20M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $5.86M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $9.83M derived: sum of 2 quarters · filed 2025-03-31 | $13.19M derived: sum of 3 quarters · filed 2025-03-31 | $15.98M 10-K · filed 2025-03-31 |
| 2023-09-30 | $3.97M 10-Q · filed 2024-11-12 | $7.33M derived: sum of 2 quarters · filed 2024-11-12 | $10.12M 10-Q · filed 2024-11-12 | $12.55M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $3.36M 10-Q · filed 2024-08-13 | $6.15M 10-Q · filed 2024-08-13 | $8.58M derived: sum of 3 quarters · filed 2024-08-13 | $13.62M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $2.79M 10-Q · filed 2024-05-14 | $5.22M derived: sum of 2 quarters · filed 2024-05-14 | $10.26M derived: sum of 3 quarters · filed 2024-05-14 | |
| 2022-12-31 | $2.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $7.47M derived: sum of 2 quarters · filed 2024-03-15 | $15.90M 10-K · filed 2024-03-15 | |
| 2022-09-30 | $5.04M 10-Q · filed 2023-11-14 | $13.48M 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |